Phase 2TerminatedINTERVENTIONAL
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
ClinicalTrials.gov · NCT02488512 · Registry updated: 2018-03-19
- Condition / research focus
- DLBCL; MCL; Recurrent Disease
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Countries with listed sites
- Italy
- Registry dates and results
- Start: 2016-12-22. Completion: 2018-02-23 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- 90Y-DOTATOC (drug) — also listed as: Y-PRRT
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Nuclear Medicin Division, IRST IRCCS
Meldola, FC, Italy
Site recruitment: Not reported